- In 2025, significant strides were made in the application of PSMA Radioligand Therapy (RLT) for oligometastatic prostate cancer, focusing on potentially curative interventions for limited disease burden. This approach, discussed at the PSMA and Beyond 2025 meeting, aims to enhance treatment efficacy and control tumor progression, marking a shift towards more targeted therapeutic strategies
- In 2025, the integration of Artificial Intelligence (AI) in radiation oncology continued to accelerate, particularly impacting adaptive radiotherapy and automated treatment planning for complex cases like oligometastatic disease. This aims to significantly improve treatment precision by accounting for anatomical changes in real-time, enhancing patient outcomes.
- In 2025, novel systemic therapies received accelerated FDA approvals for various metastatic cancers, which are relevant for managing the systemic component of oligometastatic disease. These approvals include targeted therapies and immunotherapies, highlighting the growing toolkit for personalized treatment approaches
- In 2024, the role of liquid biopsy in oligometastasis management gained further traction, with active investigation into its potential for minimal residual disease detection and monitoring treatment response. This minimally invasive approach promises to provide real-time insights into tumor dynamics, guiding adaptive therapeutic interventions
- In 2024, ongoing clinical trials continued to provide crucial insights into optimal treatment sequences and patient selection criteria for oligometastatic GI cancers, underscoring the evolving understanding of this disease state. Results from these studies are expected to further refine treatment algorithms and foster more personalized approaches.
